Skip to main content

我们经过验证的投资组合。那是我们的基础。

Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options—giving physicians and patients powerful actionable insights for navigating cancer care.

FDA-approved tissue AND blood-based testing is available for all solid tumors with FoundationOne®CDX和底座®液体CDX。此外,底座®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. There is also the option to add on immunohistochemistry (IHC) testing.

比较我们的测试

我们的测试组合

比较 底座®CDX. 底座®Liquidcdx. FoundationOne®Heme

Overview

FDA批准的基于组织的伴随所有实体瘤的伴侣诊断,表明了20+靶向疗法

118bet网娱乐

FDA批准的所有实体肿瘤的血液伴侣诊断,表明7个靶向疗法

查看CDX迹象

一种实验室开发的血液学恶性肿瘤,肉瘤或实体瘤的测试,其中需要已知或新的基因融合检测

Cancer Type

All Solid Tumors

All Solid Tumors

需要血液学恶性肿瘤,肉瘤和实体瘤,其中需要已知或新的基因融合检测

典型的周转时间

<2 weeksfrom receipt of specimen

<2 weeksfrom receipt of specimen

2 weeksfrom receipt of specimen

Number of Genes Analyzed

324(DNA)

324 genes (DNA)*

406 genes (DNA), 265 genes (RNA)

标本系列套件

底座CDX.Specimen Shipping Kit - Orange Box 底座液体CDX标本运输套件 - 深色板岩盒 底座血红标本运输套件 - 浅橙色和黄色套件

样本类型

FFPE组织

查看样本说明

Peripheral Whole Blood

查看样本说明

FFPE组织, Bone Marrow Aspirate, Peripheral Whole Blood

查看样本说明

肿瘤突变负担(TMB)

微卫星不稳定性(MSI)†

IHC测试

  • 编程的死亡配体1(PD-L1)可作为可选附加测试提供

  • FDA-approved CDx for 2 immunotherapies in specific solid tumors

  • 样本类型: FFPE Tissue – 4 USS

  • 典型的周转时间: 5 days from receipt of specimen

  • 编程的死亡配体1(PD-L1)可作为可选附加测试提供

  • FDA-approved CDx for 2 immunotherapies in specific solid tumors

  • 样本类型: FFPE Tissue – 4 USS

  • 典型的周转时间: 5 days from receipt of specimen

  • 编程的死亡配体1(PD-L1)可作为可选附加测试提供

  • FDA-approved CDx for 2 immunotherapies in specific solid tumors

  • 样本类型: FFPE Tissue – 4 USS

  • 典型的周转时间: 5 days from receipt of specimen

Additional Notes

  • 结果包括卵巢癌患者的杂合性(LOH)的丧失

  • 全体肿瘤患者鉴定医疗保险和医疗保险优势的国家报道。

  • 全体肿瘤患者鉴定医疗保险和医疗保险优势的国家报道。

*底座液体CDX是FDA批准的,以在311个基因中报告替换和诱导,包括重排和拷贝数损失BRCA1 / 2.。报告的专业服务部分报告了所有324个基因,包括BTMB,MSI-H状态和肿瘤分数的全面结果。

细节

118bet网娱乐 关于Bodaine®Liquidcdx. 1188betasia

比较By Gene

通过基因进行比较我们的测试

我们经过验证的综合基因组分析试验组合分析了数百个基因,以帮助识别患者的潜在治疗方案。使用下表通过测试比较基因覆盖范围。您可以使用橙色“添加基因”按钮在我们覆盖的基因上进行搜索。

Additional Notes

* Terc是非编码RNA基因。** TERT是具有启动子区域的基因。

†MSI地位将报道FoundationOne液体uid CDx samples determined to have high microsatellite instability.

‡Medicare and Medicare Advantage members have coverage of FoundationOne CDx and FoundationOne Liquid CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria.

开发了底座血红素及其基础药物的性能特征。博188金宝它尚未得到美国食品和药物管理局的清算或批准。有关该实验室开发测试的更多信息,请参阅技术规格foundationmedicine.com/f1h

Important Safety Information

选择

底座CDX.

BoastOne®CDX是一个基于定性的下一代测序in vitrodiagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visitwww.F1CDxLabel.com。 

底底液体CDX.

Bodaine®Liquidcdx仅用于处方使用,是基于定性的下一代测序in vitro实体肿瘤晚期癌症患者的诊断试验。试验分析利用循环无细胞DNA的324个基因,并批准用于报告311基因中的短变种,并作为鉴定可能从特定疗法治疗的患者(在预期用途中列出的表1中列出的患者诊断的伴侣诊断按照批准的治疗产品标记。可以报​​告额外的基因组发现,并且不规定的或决定性用于标记使用任何特定的治疗产品。使用测试不保证患者将与治疗匹配。否定结果不会排除发生变化的存在。对于伴随诊断突变阴性的患者应该反应到肿瘤组织测试和使用FDA批准的肿瘤组织测试确认的突变状态,如果可行。对于完整的标签,包括伴随诊断指示和完整风险信息,请访问www.f1lcdxlabel.com.